Načítá se...
Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials
We examined insulin antibody formation in patients with type 1 (T1D) or type 2 diabetes (T2D) treated with once‐daily insulin degludec (IDeg) or insulin glargine (IGlar) to evaluate the impact of antibody formation on efficacy and safety. Insulin antibodies were measured using subtraction radioimmun...
Uloženo v:
| Vydáno v: | Diabetes Obes Metab |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Blackwell Publishing Ltd
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5067686/ https://ncbi.nlm.nih.gov/pubmed/26663320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12621 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|